Zymeworks (ZYME) Times Interest Earned (2021 - 2026)
Zymeworks (ZYME) posted Times Interest Earned of -$2.43 for Q1 2026, up 94.11% sequentially from -$41.26 in Q4 2025, and up 90.06% YoY from -$1.28 in Q1 2025.
Zymeworks (ZYME) Times Interest Earned (2021 - 2026) Analysis & Trends
Zymeworks has reported Times Interest Earned for 6 years, with the latest figure at -$2.43 in Q1 2026.
- Quarterly Times Interest Earned rose 90.06% year-over-year to -$2.43 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.88 (up 81.83% YoY) and the FY2025 annual result came in at -$0.34, up 38.71% from the prior year.
- Times Interest Earned climbed to -$2.43 in Q1 2026 per ZYME's latest filing, from -$41.26 in the prior quarter.
- Over five years, Times Interest Earned peaked at $289.57 in Q4 2022 and troughed at -$48.68 in Q2 2024.
- A 5-year average of $2.89 and a median of -$17.31 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2024: Times Interest Earned soared 4037.81% in 2022, then slumped 3216.27% in 2024.
- Over 5 years, Times Interest Earned stood at $289.57 in 2022, then slumped by 105.98% to -$17.31 in 2023, then plunged by 34.11% to -$23.22 in 2024, then plunged by 77.74% to -$41.26 in 2025, then surged by 94.11% to -$2.43 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$2.43, -$41.26, and -$20.53 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | -0.49 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.49 |
| Mar 31, 2026 | -2.43 |
| Dec 31, 2025 | -41.26 |
| Sep 30, 2025 | -20.53 |
| Jun 30, 2025 | -0.03 |
| Mar 31, 2025 | -24.44 |
| Dec 31, 2024 | -23.22 |
| Sep 30, 2024 | -35.15 |
| Jun 30, 2024 | -48.68 |
| Mar 31, 2024 | -28.19 |
| Dec 31, 2023 | -17.31 |
| Sep 30, 2023 | -1.07 |
| Jun 30, 2023 | -1.70 |
| Mar 31, 2023 | -0.85 |
| Dec 31, 2022 | 289.57 |
| Sep 30, 2022 | -1.43 |
| Dec 31, 2021 | -7.35 |